CR10037A - Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida - Google Patents

Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida

Info

Publication number
CR10037A
CR10037A CR10037A CR10037A CR10037A CR 10037 A CR10037 A CR 10037A CR 10037 A CR10037 A CR 10037A CR 10037 A CR10037 A CR 10037A CR 10037 A CR10037 A CR 10037A
Authority
CR
Costa Rica
Prior art keywords
preparation
diazapanil
piperacinil
benzamida
derivatives
Prior art date
Application number
CR10037A
Other languages
English (en)
Inventor
S Mani Neelakandha
C Palmer David
R Pandit Chennagiri
B Reyes Mayra
Xiao Tong
Cesco-Cancian Sergio
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10037A publication Critical patent/CR10037A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención está dirigida a procedimientos novedosos para la preparación de piperacinil y diazepanil benzamidas sustituidas, útiles para el tratamiento de trastornos y condiciones mediadas por el receptor de la histamina.
CR10037A 2005-10-31 2008-05-30 Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida CR10037A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73194105P 2005-10-31 2005-10-31

Publications (1)

Publication Number Publication Date
CR10037A true CR10037A (es) 2008-11-24

Family

ID=37766699

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10037A CR10037A (es) 2005-10-31 2008-05-30 Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida

Country Status (19)

Country Link
US (2) US7728129B2 (es)
EP (2) EP2404911A1 (es)
JP (1) JP2009513702A (es)
KR (1) KR20080067365A (es)
CN (1) CN101389617A (es)
AR (1) AR056750A1 (es)
AU (1) AU2006309077A1 (es)
BR (1) BRPI0617947A2 (es)
CA (1) CA2628210A1 (es)
CR (1) CR10037A (es)
EA (2) EA201001799A1 (es)
EC (1) ECSP088416A (es)
IL (1) IL190963A0 (es)
NO (1) NO20082459L (es)
NZ (1) NZ567357A (es)
SV (1) SV2009002893A (es)
TW (1) TW200736239A (es)
WO (1) WO2007053427A2 (es)
ZA (1) ZA200804732B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
ES2620818T3 (es) * 2006-12-14 2017-06-29 Janssen Pharmaceutica N.V. Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida
WO2009030716A1 (en) 2007-09-06 2009-03-12 Glaxo Group Limited Piperazine derivative having affinity for the histamine h3 receptor
CN111610246B (zh) * 2019-02-25 2023-05-12 中国科学院上海有机化学研究所 用于质谱检测的羧基衍生化试剂组合物及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
SK5202000A3 (en) 2000-04-07 2001-12-03 Slovakofarma As Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4- inyl)-n-methyl-1-naphthalenemethylamine (terbinaphin)
EP1296939B1 (de) * 2000-07-05 2005-11-09 Basf Aktiengesellschaft Verfahren zur herstellung von trioximderivaten
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US6548670B1 (en) 2001-07-19 2003-04-15 Air Products And Chemicals, Inc. Methods for preparing 5- and 6-benzyl-functionalized quinoxalines
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
ATE449766T1 (de) * 2002-10-23 2009-12-15 Janssen Pharmaceutica Nv Piperazinyl- und diazapanylbenzamide und- benzothioamide
WO2005021525A1 (en) * 2003-08-27 2005-03-10 Janssen Pharmaceutica, N.V. Aryl piperidine amides
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
PT1924585E (pt) * 2005-08-29 2012-01-19 Sanofi Aventis Us Llc Nova forma cristalina de um derivado de piridazino[4,5-b]indole
DE602006019822D1 (de) * 2005-09-13 2011-03-10 Sicor Inc Reines rocuroniumbromid
KR20090064400A (ko) * 2006-09-28 2009-06-18 머크 앤드 캄파니 인코포레이티드 Hdac 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-hdac 억제제 킬레이트 착물의 약제학적 조성물
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists

Also Published As

Publication number Publication date
EA200801239A1 (ru) 2008-08-29
EA014905B1 (ru) 2011-02-28
US20070197508A1 (en) 2007-08-23
IL190963A0 (en) 2008-12-29
ECSP088416A (es) 2008-05-30
BRPI0617947A2 (pt) 2011-08-09
SV2009002893A (es) 2009-06-18
US20100197689A1 (en) 2010-08-05
AU2006309077A1 (en) 2007-05-10
NZ567357A (en) 2011-05-27
JP2009513702A (ja) 2009-04-02
ZA200804732B (en) 2009-11-25
NO20082459L (no) 2008-07-22
CN101389617A (zh) 2009-03-18
EP2404911A1 (en) 2012-01-11
US7728129B2 (en) 2010-06-01
WO2007053427A2 (en) 2007-05-10
KR20080067365A (ko) 2008-07-18
WO2007053427A3 (en) 2007-07-12
EP1951700A2 (en) 2008-08-06
EA201001799A1 (ru) 2011-06-30
AR056750A1 (es) 2007-10-24
CA2628210A1 (en) 2007-05-10
TW200736239A (en) 2007-10-01

Similar Documents

Publication Publication Date Title
ECSP099405A (es) Procedimiento para la preparación de derivados benzimida piperacinilo y diazepanilo
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
UY30931A1 (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
SMT201200017B (it) Nuovi antagonisti P2X7R e il loro uso.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
DOP2011000064A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilaminio-metil] benzamida (ms-275)
ECSP11011482A (es) Piperidinas sustituidas
CR10036A (es) Procedimientos para la preparación de derivados de ciclopropilamida
ECSP088416A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida
DOP2003000587A (es) AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
CY1110087T1 (el) Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο
DK1893597T3 (da) AMPA-receptorpotentiatorer
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
GT200800195A (es) Procedimiento para la preparación de derivados de ciclopropilamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)